BioSpace News Archive

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the 41st Annual J.P. Morgan Healthcare Conference.

Alphalyse has performed the world’s first GMP-certified mass spectrometry (MS)-based Host Cell Protein (HCP) analysis for product release testing for Phase 3 clinical trial, after being certified by the Danish Health and Medicines Authority to perform quality control of biological API using MS-based HCP analysis under GMP.

Ascendis Pharma A/S announced that the Company is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference.

MiMedx Group, Inc., a pioneer and leader in placental biologics, announced that it has appointed Ricci S. Whitlow as Chief Operating Officer, a role that will lead the efforts of the Company’s manufacturing, supply chain, procurement, quality, and regulatory functions.

Anthos Therapeutics today announced that it has enrolled the first patient in LILAC-TIMI 76, a Phase 3 study to evaluate the efficacy and safety of abelacimab in high-risk patients with atrial fibrillation (AF) deemed unsuitable for current anticoagulants by their physician.

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9, 2023 at 4:30 p.m. PT ( 7:30 p.m.)

Abintus Bio Appoints Hebrew University Researcher Lior Nissim, Ph.D., As Head of Synthetic Biology and Concurrently Enters Agreement for Next-Generation, Synthetic Biology Technology to Enable In Vivo Genetic Medicines.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2023 on Wednesday, February 1, after the market closes.

Halberd’s previous research on development of a monoclonal antibody (mAb) against COVID-19 (SARS-COV-2) was found to enhance the effectiveness of the leading commercial COVID antibody by 44.4%.

Standard BioTools Inc. today announced the appointment of Betsy Jensen as Chief Human Resources Officer.